Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling
Wenjie Wei, … , Xu Zhang, Yan Huang
Wenjie Wei, … , Xu Zhang, Yan Huang
Published February 18, 2025
Citation Information: J Clin Invest. 2025;135(8):e186648. https://doi.org/10.1172/JCI186648.
View: Text | PDF
Research Article Cell biology Immunology

Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling

  • Text
  • PDF
Abstract

Tumor cells often employ many ways to restrain type I IFN signaling to evade immune surveillance. However, whether cellular amino acid metabolism regulates this process remains unclear, and its effects on antitumor immunity are relatively unexplored. Here, we found that asparagine inhibited IFN-I signaling and promoted immune escape in bladder cancer. Depletion of asparagine synthetase (ASNS) strongly limited in vivo tumor growth in a CD8+ T cell–dependent manner and boosted immunotherapy efficacy. Moreover, clinically approved L-asparaginase (ASNase),synergized with anti–PD-1 therapy in suppressing tumor growth. Mechanistically, asparagine can directly bind to RIG-I and facilitate CBL-mediated RIG-I degradation, thereby suppressing IFN signaling and antitumor immune responses. Clinically, tumors with higher ASNS expression show decreased responsiveness to immune checkpoint inhibitor therapy. Together, our findings uncover asparagine as a natural metabolite to modulate RIG-I–mediated IFN-I signaling, providing the basis for developing the combinatorial use of ASNase and anti–PD-1 for bladder cancer.

Authors

Wenjie Wei, Hongzhao Li, Shuo Tian, Chi Zhang, Junxiao Liu, Wen Tao, Tianwei Cai, Yuhao Dong, Chuang Wang, Dingyi Lu, Yakun Ai, Wanlin Zhang, Hanfeng Wang, Kan Liu, Yang Fan, Yu Gao, Qingbo Huang, Xin Ma, Baojun Wang, Xu Zhang, Yan Huang

×

Figure 5

Asparagine promotes the CBL-mediated proteasomal degradation of RIG-I.

Options: View larger image (or click on image) Download as PowerPoint
Asparagine promotes the CBL-mediated proteasomal degradation of RIG-I.
(...
(A) HEK293T cells were transfected with Flag-RIG-I and HA-CBL and cultured in complete medium (Comp) and medium added Asn (1 mM) for 48 hours, followed by coimmunoprecipitation and immunoblotting analysis with the indicated antibodies. (B) Flag-RIG-I–overexpressed HEK293T cells were cultured in complete medium (Comp) or medium added Asn (1 mM), and those cotransfected with a control and HA-CBL overexpression plasmid for 48 hours, followed by coimmunoprecipitation and immunoblotting analysis with the indicated antibodies. (C) Purified Flag-RIG-I proteins were incubated with the indicated proteins in the presence or absence of 1 mM Asn for 2 hours. Mixtures were analyzed by Western blot. (D) MST measurement of the interaction between Asn and purified RIG-I. Kd value was automatically by the curve fitting. (E) MST measurement of the interaction between Asn and purified CBL. (F) Western blot of the indicated proteins in MBT2 cells cultured in complete medium (Comp) or medium added Asn (1 mM), and those cotransfected with si-NC, si-Cbl#1 or si-Cbl#2. (G) qRT-PCR revealed the expression levels of Ifn-β and Ccl5 in MBT2 cells cultured in complete medium (Comp) or medium added Asn (1 mM), and those cotransfected with si-NC, si-Cbl#1, or si-Cbl#2. (H) Tumor growth curves and tumor weight of immunocompetent C3H mice (n = 6) injected subcutaneously with indicated MBT2 cells. (I) Tumor infiltrating CD8+ T cells from transplanted MBT2 tumors (n = 6) in C3H mice were analyzed by flow cytometry. Data were mean ± SD. Statistical significance was calculated by 2-way ANOVA for G–I. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts